Skip to main content
. Author manuscript; available in PMC: 2016 Feb 8.
Published in final edited form as: J Bone Miner Res. 2013 Jan;28(1):92–107. doi: 10.1002/jbmr.1732

Fig. 7.

Fig. 7

Cells from murine mammary cell line (66.1) were treated acutely for 3 hours with JWH015 (1000 ng) and/or SR144528 (100 ng) (n = 6 wells per treatment group) Quantitative ELISA was used to measure amount of each inflammatory mediator secreted by cells, reported as % relative expression of secretion compared to control (vehicle-treated cells). (A) JWH015 treatment alone significantly reduces expression of MCP-1 (p = 0.02) but not in the presence of SR144528 (p < 0.0001). (B) JWH015 treatment alone significantly reduces expression of IL6 (p = 0.02) but this effect is not seen with SR144528 treatment. (C) JWH015 treatment significantly reduces expression of TNFα but not in the presence of SR144528. (D) Twenty-four–hour IL-6 treatment (1 ng) significantly increases viability (p < 0.00001). Twenty-four–hour JWH015 treatment attenuates IL6-induced effect on viability (p < 0.00001). One-hour SR144528 pretreatment inhibits 24-hour JWH015 attenuation of IL6-induced increase in viability (p < 0.00001), as evidenced by SBR assay.